Psychedelics: From Breakthrough to Backlash—and Back Again

What “Psychedelics: Where we are now, why we got here, what we must do” reveals about the past, present, and future of psychedelic science

https://www.sciencedirect.com/science/article/pii/S0028390818300753

Psychedelics didn’t quietly disappear.

They were pushed out.

And now, decades later, they’re coming back—not as counterculture symbols, but as serious contenders in the fight against mental illness.

The article “Psychedelics: Where we are now, why we got here, what we must do” traces this full arc—from early scientific promise to political shutdown to modern resurgence.

And the story is more complicated than most people think.

The Forgotten Era of Scientific Optimism

In the 1940s and 50s, psychedelics weren’t fringe—they were mainstream research tools.

After the discovery of LSD, scientists began exploring its potential to treat:

• Depression

• Anxiety

• Addiction

• Trauma

By the 1960s:

• Over 1,000 scientific papers had been published

• Tens of thousands of patients had received psychedelic-assisted therapy

There was real optimism that these substances might revolutionize psychiatry.

What Went Wrong

The collapse of psychedelic research wasn’t driven purely by science.

It was driven by culture and politics.

As psychedelics moved from labs into the public sphere:

• Association with counterculture movements grew

• Public concern about misuse increased

• Media narratives turned negative

The result was the 1970 Controlled Substances Act, which placed psychedelics in the most restrictive category—Schedule I.

That meant:

• No accepted medical use

• High regulatory barriers

• Severe limitations on research

Research didn’t technically stop.

But it became so difficult that, for decades, it effectively did.

The Cost of Stopping the Science

One of the article’s most important points is not just that research slowed—but what that might have cost.

For over 50 years:

• Large-scale clinical trials never happened

• Promising early findings were left unresolved

• Entire lines of inquiry were abandoned

And all of this happened during a period when:

Mental health disorders were increasing—and treatments were often failing.

Today, many conditions like:

• Treatment-resistant depression

• PTSD

• Addiction

remain difficult to treat with existing therapies.

The Mental Health Crisis Driving Renewed Interest

The article is clear about the scale of the problem:

• Millions of people experience depression and anxiety annually

• Substance use disorders cost hundreds of billions of dollars

• Suicide and overdose rates continue to rise

At the same time, pharmaceutical innovation in psychiatry has slowed, with many companies scaling back research due to high failure rates.

This creates a powerful incentive:

Look again at treatments we may have abandoned too quickly.

The Psychedelic Renaissance

Since the 1990s, research has cautiously restarted.

Modern studies—using stricter methods and controls—are exploring psychedelics for:

• Depression

• PTSD

• Addiction

• End-of-life anxiety

Some findings are striking:

• Single or few sessions can produce lasting improvements

• Effects can persist for months or even longer

• Benefits often occur where traditional treatments fail

One notable development:

• MDMA-assisted therapy has received Breakthrough Therapy designation for PTSD from the FDA

This signals that regulators are beginning to take the field seriously again.

Why This Isn’t Simple

Despite the excitement, the article emphasizes caution.

There are still major challenges:

1. Regulatory Barriers

Schedule I classification continues to:

• Limit funding

• Increase administrative burden

• Slow down research

2. Scientific Gaps

Most studies are:

• Small

• Early-stage

• Not yet definitive

Large-scale trials are still needed.

3. Cultural Stigma

Decades of association with misuse still influence:

• Public perception

• Policy decisions

• Patient willingness

More Than Medicine: A Shift in Perspective

One of the deeper arguments in the article is that psychedelics may not just be treatments—they may also help us understand the brain itself.

Research is revealing:

• How consciousness works

• How mental disorders emerge

• How rigid patterns of thought can be disrupted

In that sense, psychedelics are both:

• Therapeutic tools

• Scientific instruments

What Needs to Happen Next

The authors don’t just describe the problem—they outline a path forward.

Key priorities include:

• Expanding clinical trials

• Reducing unnecessary regulatory barriers

• Increasing funding for research

• Encouraging collaboration across science, policy, and medicine

They even propose large-scale research summits to coordinate global efforts

The message is clear:

Progress will require not just science—but coordination and political will.

Final Take

The history of psychedelics is not just a scientific story.

It’s a story about:

• Culture

• Fear

• Policy

• And missed opportunities

Now, with mental health challenges growing and current treatments falling short, the question is no longer whether psychedelics are controversial.

It’s whether we can afford to ignore them.

Sean J. Belouin, Jack E. Henningfield, Psychedelics: Where we are now, why we got here, what we must do, Neuropharmacology, Volume 142, 2018, Pages 7-19, ISSN 0028-3908, https://doi.org/10.1016/